Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
18
BPTH Quote, Financials, Valuation and Earnings
Last price:
$0.07
Seasonality move
:
23.12%
Day range:
$0.07 - $0.08
52-week range:
$0.05 - $0.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
9.98x
Volume:
11.6K
Avg. volume:
20.8K
1-year change:
--
Market cap:
$548.3K
Revenue:
--
EPS (TTM):
-$1.72
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BPTH
Bio-Path Holdings, Inc.
|
-- | -$0.40 | -- | -65.52% | $2.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.21 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BPTH
Bio-Path Holdings, Inc.
|
$0.07 | $2.00 | $548.3K | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.85 | $0.85 | $611.2M | 8.15x | $0.80 | 0% | 9.42x |
|
NNVC
NanoViricides, Inc.
|
$1.19 | $6.50 | $21.4M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.86 | $2.00 | $706.9K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BPTH
Bio-Path Holdings, Inc.
|
-7.17% | 0.385 | 33.92% | 0.00x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BPTH
Bio-Path Holdings, Inc.
|
-$41K | -$4.6M | -- | -- | -- | -$283K |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Bio-Path Holdings, Inc. vs. Competitors
-
Which has Higher Returns BPTH or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Bio-Path Holdings, Inc.'s net margin of -255.85%. Bio-Path Holdings, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital BPTHBio-Path Holdings, Inc.-- -$0.55 -$6.7M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About BPTH or NBY?
Bio-Path Holdings, Inc. has a consensus price target of $2.00, signalling upside risk potential of 2930.3%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that Bio-Path Holdings, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Bio-Path Holdings, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BPTHBio-Path Holdings, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is BPTH or NBY More Risky?
Bio-Path Holdings, Inc. has a beta of -0.058, which suggesting that the stock is 105.835% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock BPTH or NBY?
Bio-Path Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Bio-Path Holdings, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BPTH or NBY?
Bio-Path Holdings, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Bio-Path Holdings, Inc.'s net income of -$4.6M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Bio-Path Holdings, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Path Holdings, Inc. is -- versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BPTHBio-Path Holdings, Inc.-- -- -- -$4.6M NBYNovaBay Pharmaceuticals, Inc.9.42x 8.15x $521K -$1.3M
-
Which has Higher Returns BPTH or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Bio-Path Holdings, Inc.'s net margin of --. Bio-Path Holdings, Inc.'s return on equity of -- beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital BPTHBio-Path Holdings, Inc.-- -$0.55 -$6.7M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About BPTH or NNVC?
Bio-Path Holdings, Inc. has a consensus price target of $2.00, signalling upside risk potential of 2930.3%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 446.22%. Given that Bio-Path Holdings, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Bio-Path Holdings, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BPTHBio-Path Holdings, Inc.0 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is BPTH or NNVC More Risky?
Bio-Path Holdings, Inc. has a beta of -0.058, which suggesting that the stock is 105.835% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock BPTH or NNVC?
Bio-Path Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Path Holdings, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BPTH or NNVC?
Bio-Path Holdings, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Bio-Path Holdings, Inc.'s net income of -$4.6M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Bio-Path Holdings, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Path Holdings, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BPTHBio-Path Holdings, Inc.-- -- -- -$4.6M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns BPTH or OGEN?
Oragenics, Inc. has a net margin of -- compared to Bio-Path Holdings, Inc.'s net margin of --. Bio-Path Holdings, Inc.'s return on equity of -- beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital BPTHBio-Path Holdings, Inc.-- -$0.55 -$6.7M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About BPTH or OGEN?
Bio-Path Holdings, Inc. has a consensus price target of $2.00, signalling upside risk potential of 2930.3%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 132.83%. Given that Bio-Path Holdings, Inc. has higher upside potential than Oragenics, Inc., analysts believe Bio-Path Holdings, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BPTHBio-Path Holdings, Inc.0 0 0 OGENOragenics, Inc.1 0 0 -
Is BPTH or OGEN More Risky?
Bio-Path Holdings, Inc. has a beta of -0.058, which suggesting that the stock is 105.835% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock BPTH or OGEN?
Bio-Path Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Path Holdings, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BPTH or OGEN?
Bio-Path Holdings, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Bio-Path Holdings, Inc.'s net income of -$4.6M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Bio-Path Holdings, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Path Holdings, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BPTHBio-Path Holdings, Inc.-- -- -- -$4.6M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns BPTH or PTN?
Palatin Technologies has a net margin of -- compared to Bio-Path Holdings, Inc.'s net margin of --. Bio-Path Holdings, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BPTHBio-Path Holdings, Inc.-- -$0.55 -$6.7M PTNPalatin Technologies-- -- -- -
What do Analysts Say About BPTH or PTN?
Bio-Path Holdings, Inc. has a consensus price target of $2.00, signalling upside risk potential of 2930.3%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Bio-Path Holdings, Inc., analysts believe Palatin Technologies is more attractive than Bio-Path Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BPTHBio-Path Holdings, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is BPTH or PTN More Risky?
Bio-Path Holdings, Inc. has a beta of -0.058, which suggesting that the stock is 105.835% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock BPTH or PTN?
Bio-Path Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Path Holdings, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BPTH or PTN?
Bio-Path Holdings, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Bio-Path Holdings, Inc.'s net income of -$4.6M is higher than Palatin Technologies's net income of --. Notably, Bio-Path Holdings, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Path Holdings, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BPTHBio-Path Holdings, Inc.-- -- -- -$4.6M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns BPTH or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Bio-Path Holdings, Inc.'s net margin of --. Bio-Path Holdings, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital BPTHBio-Path Holdings, Inc.-- -$0.55 -$6.7M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About BPTH or TOVX?
Bio-Path Holdings, Inc. has a consensus price target of $2.00, signalling upside risk potential of 2930.3%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3559.17%. Given that Theriva Biologics, Inc. has higher upside potential than Bio-Path Holdings, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Bio-Path Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BPTHBio-Path Holdings, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is BPTH or TOVX More Risky?
Bio-Path Holdings, Inc. has a beta of -0.058, which suggesting that the stock is 105.835% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock BPTH or TOVX?
Bio-Path Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Path Holdings, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BPTH or TOVX?
Bio-Path Holdings, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Bio-Path Holdings, Inc.'s net income of -$4.6M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Bio-Path Holdings, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Path Holdings, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BPTHBio-Path Holdings, Inc.-- -- -- -$4.6M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
